143 related articles for article (PubMed ID: 34308004)
21. Teriflunomide: A possible effective drug for the comprehensive treatment of COVID-19.
Rabie AM
Curr Res Pharmacol Drug Discov; 2021; 2():100055. PubMed ID: 34870153
[TBL] [Abstract][Full Text] [Related]
22. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
23. Potential combination therapy using twenty phytochemicals from twenty plants to prevent SARS- CoV-2 infection: An in silico Approach.
Dey D; Dey N; Ghosh S; Chandrasekaran N; Mukherjee A; Thomas J
Virusdisease; 2021 Mar; 32(1):108-116. PubMed ID: 33842675
[TBL] [Abstract][Full Text] [Related]
24. Repurposing FDA-approved drugs to fight COVID-19 using
Mahdian S; Zarrabi M; Panahi Y; Dabbagh S
Inform Med Unlocked; 2021; 23():100541. PubMed ID: 33649734
[TBL] [Abstract][Full Text] [Related]
25. Virtual screenings of the bioactive constituents of tea, prickly chaff, catechu, lemon, black pepper, and synthetic compounds with the main protease (Mpro) and human angiotensin-converting enzyme 2 (ACE 2) of SARS-CoV-2.
Emon NU; Alam MM; Akter I; Akhter S; Sneha AA; Irtiza M; Afroj M; Munni A; Chowdhury MH; Hossain S
Futur J Pharm Sci; 2021; 7(1):121. PubMed ID: 34150913
[TBL] [Abstract][Full Text] [Related]
26. In silico and in vitro screening of licensed antimalarial drugs for repurposing as inhibitors of hepatitis E virus.
Tietcheu Galani BR; Ayissi Owona VB; Guemmogne Temdie RJ; Metzger K; Atsama Amougou M; Djamen Chuisseu PD; Fondjo Kouam A; Ngounoue Djuidje M; Aliouat-Denis CM; Cocquerel L; Fewou Moundipa P
In Silico Pharmacol; 2021; 9(1):35. PubMed ID: 33959472
[TBL] [Abstract][Full Text] [Related]
27. The Computational Intervention of Macrolide Antibiotics in the Treatment of COVID-19.
Anwar F; Altayb HN; Al-Abbasi FA; Kumar V; Kamal MA
Curr Pharm Des; 2021; 27(9):1202-1210. PubMed ID: 33550966
[TBL] [Abstract][Full Text] [Related]
28. Computational Evidences of Phytochemical Mediated Disruption of PLpro Driven Replication of SARS-CoV-2: A Therapeutic Approach against COVID-19.
Balkrishna A; Mittal R; Arya V
Curr Pharm Biotechnol; 2021; 22(10):1350-1359. PubMed ID: 33176643
[TBL] [Abstract][Full Text] [Related]
29. Searching for target-specific and multi-targeting organics for Covid-19 in the Drugbank database with a double scoring approach.
Murugan NA; Kumar S; Jeyakanthan J; Srivastava V
Sci Rep; 2020 Nov; 10(1):19125. PubMed ID: 33154404
[TBL] [Abstract][Full Text] [Related]
30. Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An
Alexpandi R; De Mesquita JF; Pandian SK; Ravi AV
Front Microbiol; 2020; 11():1796. PubMed ID: 32793181
[TBL] [Abstract][Full Text] [Related]
31. Identifying Effective Antiviral Drugs Against SARS-CoV-2 by Drug Repositioning Through Virus-Drug Association Prediction.
Peng L; Tian X; Shen L; Kuang M; Li T; Tian G; Yang J; Zhou L
Front Genet; 2020; 11():577387. PubMed ID: 33193695
[TBL] [Abstract][Full Text] [Related]
32. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
33. Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus.
Umar HI; Siraj B; Ajayi A; Jimoh TO; Chukwuemeka PO
J Genet Eng Biotechnol; 2021 Jan; 19(1):16. PubMed ID: 33492492
[TBL] [Abstract][Full Text] [Related]
34. β-Carboline alkaloids induce structural plasticity and inhibition of SARS-CoV-2 nsp3 macrodomain more potently than remdesivir metabolite GS-441524: computational approach.
Ayipo YO; Yahaya SN; Babamale HF; Ahmad I; Patel H; Mordi MN
Turk J Biol; 2021; 45(4):503-517. PubMed ID: 34803450
[TBL] [Abstract][Full Text] [Related]
35.
Gurung AB
Gene Rep; 2020 Dec; 21():100860. PubMed ID: 32875166
[TBL] [Abstract][Full Text] [Related]
36. Current targets and drug candidates for prevention and treatment of SARS-CoV-2 (COVID-19) infection.
Goyal RK; Majeed J; Tonk R; Dhobi M; Patel B; Sharma K; Apparsundaram S
Rev Cardiovasc Med; 2020 Sep; 21(3):365-384. PubMed ID: 33070542
[TBL] [Abstract][Full Text] [Related]
37. Identification of promising drug candidates against NSP16 of SARS-CoV-2 through computational drug repurposing study.
Vijayan V; Pant P; Vikram N; Kaur P; Singh TP; Sharma S; Sharma P
J Biomol Struct Dyn; 2021 Oct; 39(17):6713-6727. PubMed ID: 32741322
[TBL] [Abstract][Full Text] [Related]
38. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2
Khan SA; Zia K; Ashraf S; Uddin R; Ul-Haq Z
J Biomol Struct Dyn; 2021 Apr; 39(7):2607-2616. PubMed ID: 32238094
[TBL] [Abstract][Full Text] [Related]
39. Interaction of
Aminu S; Ibrahim MA; Sallau AB
Beni Suef Univ J Basic Appl Sci; 2021; 10(1):48. PubMed ID: 34458381
[TBL] [Abstract][Full Text] [Related]
40.
Ibrahim MAA; Abdelrahman AHM; Hegazy MF
J Biomol Struct Dyn; 2021 Sep; 39(15):5756-5767. PubMed ID: 32684114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
